Divi's Lab.

Who are in the management team of Divi's Lab.?

As of March 2022, the management team of Divi's Lab includes Murali K Divi (Chairman & Managing Director), Kiran S Divi (CEO), and several other directors and independent members responsible for the company's strategic direction.

As of March 2022, the management team of Divi's Lab includes the following key individuals:<BR><BR>1. Murali K Divi - Chairman & Managing Director<BR>2. N V Ramana - Executive Director<BR>3. Madhusudana Rao Divi - Whole Time Director (Projects)<BR>4. Kiran S Divi - Whole Time Director & CEO<BR>5. Nilima Motaparti - Whole Time Director - Commercial<BR>6. G Suresh Kumar - Independent Director<BR>7. Ranga Rao Ravipati - Independent Director<BR>8. K V K Seshavataram - Independent Director<BR>9. Ramesh B V Nimmagadda - Chairman (Non-Executive) & Independent Director<BR>10. S Ganapaty - Independent Director<BR>11. Sunaina Singh - Independent Director<BR>12. Kosaraju Veerayya Chowdary - Independent Director<BR>13. Satish Choudhury - Company Secretary & Compliance Officer<BR><BR>This team is responsible for the strategic direction and management of the company.

What does Divi's Lab. do?

Divi's Laboratories Limited is a prominent pharmaceutical company specializing in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals. As of March 2025, it reported net sales of ₹2,585 Cr and a net profit of ₹662 Cr, with a market cap of ₹173,306 Cr.

Overview:<BR>Divi's Laboratories Limited is a leading pharmaceutical company engaged in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals, operating within the Pharmaceuticals & Biotechnology industry and classified as a Large Cap company.<BR><BR>History:<BR>Divi's Laboratories was incorporated in the year 1990. The latest quarterly results reported are for March 2025, showcasing the company's ongoing operations and market presence.<BR><BR>Financial Snapshot:<BR>- Net Sales: 2,585 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 662 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 173,306 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 80.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.45%<BR>- Debt-Equity: -0.25<BR>- Return on Equity: 14.64%<BR>- Price to Book: 11.74<BR><BR>Contact Details:<BR>Address: 1-72-23(P)/DIVIS/303 Divi Tower, Cyber Hills Gachibowli Hyderabad Telangana : 500032<BR>Tel: 91-40-23786300/23786352/400<BR>Email: mail@divislabs.com<BR>Website: http://www.divislaboratories.com

What is the bonus history of the Divi's Lab.?

Divi's Laboratories has a history of issuing bonus shares, with the most recent being a 1:1 bonus announced on September 23, 2015, and a prior 1:1 bonus on August 1, 2009. This reflects the company's consistent practice of rewarding shareholders.

Divi's Laboratories has a history of issuing bonuses. The most recent bonus was a 1:1 bonus issue, which was announced with an ex-date of September 23, 2015, and the record date was September 26, 2015. Prior to that, the company also issued a 1:1 bonus on August 1, 2009, with an ex-date of July 30, 2009. This indicates that Divi's Lab has a consistent practice of rewarding its shareholders through bonus shares.

Has Divi's Lab. declared dividend?

Divis Laboratories Ltd has declared a 1500% dividend, amounting to ₹30 per share, with an ex-date of August 2, 2024. The company has shown strong total returns over various periods, particularly with a 169.61% total return over the past five years.

Divis Laboratories Ltd has declared a 1500% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1500%<BR>- Amount per share: 30<BR>- Ex-date: 02 Aug 24<BR><BR>Dividend Yield: 0.45%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 5.9%, the dividend return was 0%, resulting in a total return of 5.9%.<BR><BR>Over the past year, the price return was 45.73%, the dividend return was 0.67%, leading to a total return of 46.4%.<BR><BR>In the 2-year period, the price return was 84.08%, the dividend return was 1.67%, culminating in a total return of 85.75%.<BR><BR>For the 3-year period, the price return was 85.98%, the dividend return was 2.50%, resulting in a total return of 88.48%.<BR><BR>In the last 4 years, the price return was 52.87%, the dividend return was 2.55%, leading to a total return of 55.42%.<BR><BR>Over the past 5 years, the price return was 164.6%, the dividend return was 5.01%, resulting in a total return of 169.61%.<BR><BR>Overall, Divis Laboratories Ltd has declared a significant dividend, and the total returns over various periods indicate strong performance, particularly in the long term, with substantial price appreciation and increasing dividend contributions.

Who are the peers of the Divi's Lab.?

Divi's Lab. peers include Sun Pharma, Cipla, Torrent Pharma, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., Lupin, Aurobindo Pharma, Abbott India, and Alkem Lab. Divi's Lab. has the highest 1-year return at 51.69% among its peers, while Zydus Lifesci. has the lowest at -10.04%.

Peers: The peers of Divi's Lab. are Sun Pharma.Inds., Cipla, Torrent Pharma, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., Lupin, Aurobindo Pharma, Abbott India, and Alkem Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Torrent Pharma, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., Aurobindo Pharma, Abbott India, and Alkem Lab., while Average management risk is found at Lupin. Growth is excellent at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., and Lupin, while Divi's Lab., Torrent Pharma, and Aurobindo Pharma show below average growth. Excellent capital structure is noted for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., Aurobindo Pharma, and Abbott India, while good capital structure is found at Torrent Pharma and Lupin.<BR><BR>Return Snapshot: Divi's Lab. has a 1-year return of 51.69%, which is the highest among its peers, while Zydus Lifesci. has the lowest at -10.04%. Additionally, peers with negative six-month returns include Sun Pharma.Inds., Cipla, Torrent Pharma, Mankind Pharma, Zydus Lifesci., Lupin, Aurobindo Pharma, and Alkem Lab.

Who are the top shareholders of the Divi's Lab.?

The top shareholders of Divi's Lab include promoter Nilima Prasad Divi with 20.34%, foreign institutional investors holding 18.01%, mutual funds at 12.83%, and the Life Insurance Corporation of India as the largest public shareholder with 5.63%. Individual investors own 7.17% of the shares.

The top shareholders of Divi's Lab include the promoters, who hold the majority of the shares. Notably, Nilima Prasad Divi is the promoter with the highest holding at 20.34%. In addition, foreign institutional investors (FIIs) hold 18.01% of the shares, while mutual funds collectively account for 12.83% through 39 schemes. The highest public shareholder is the Life Insurance Corporation of India, which holds 5.63%. Individual investors also have a stake, representing 7.17% of the total shares.

How big is Divi's Lab.?

As of 24th July, Divis Laboratories Ltd has a market capitalization of 176,072.00 Cr, with recent net sales of 9,360.00 Cr and a net profit of 2,191.00 Cr. The company has shareholder's funds of 14,969.00 Cr and total assets of 16,921.00 Cr.

As of 24th July, Divis Laboratories Ltd has a market capitalization of 176,072.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Divis Laboratories reported net sales of 9,360.00 Cr and a net profit of 2,191.00 Cr.<BR><BR>For the latest annual period ending March 2025, the company has shareholder's funds amounting to 14,969.00 Cr and total assets of 16,921.00 Cr.

When is the next results date for Divi's Lab.?

Divi's Lab. will announce its results on 07 November 2025.

Divi's Lab. will declare its results on 07 November 2025.

How has been the historical performance of Divi's Lab.?

Divi's Lab has shown consistent growth in net sales and profitability, with net sales increasing from 4,946.26 Cr in Mar'19 to 9,360.00 Cr in Mar'25, and profit after tax rising to 2,191.00 Cr in Mar'25. The company's total assets also grew significantly, reflecting a strong financial performance overall.

Answer:<BR>The historical performance of Divi's Lab shows a consistent growth trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Divi's Lab has demonstrated a steady increase in net sales, rising from 4,946.26 Cr in Mar'19 to 9,360.00 Cr in Mar'25. The total operating income followed a similar trajectory, reaching 9,360.00 Cr in Mar'25, up from 7,767.00 Cr in Mar'23. Operating profit (PBDIT) also saw fluctuations, peaking at 3,995.81 Cr in Mar'22 before settling at 3,320.00 Cr in Mar'25. Profit before tax increased to 2,916.00 Cr in Mar'25 from 2,163.00 Cr in Mar'24, while profit after tax reached 2,191.00 Cr in Mar'25, up from 1,600.00 Cr in Mar'24. The company's total assets grew significantly from 8,531.32 Cr in Mar'20 to 16,921.00 Cr in Mar'25, reflecting a robust expansion. Total liabilities also increased, but at a slower pace, indicating a strengthening balance sheet. Cash flow from operating activities improved to 1,653.00 Cr in Mar'25, contributing to a net cash inflow of 50.00 Cr for the year. Overall, Divi's Lab has shown resilience and growth in its financial performance across multiple metrics.

Is Divi's Lab. technically bullish or bearish?

As of December 1, 2025, Divi's Lab shows a mildly bullish trend, supported by bullish weekly MACD and Bollinger Bands, despite mixed signals from monthly indicators.

As of 1 December 2025, the technical trend for Divi's Lab has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, supporting a positive outlook. Daily moving averages are bullish, reinforcing the mildly bullish stance. However, the KST shows a bullish weekly trend but is mildly bearish monthly, and Dow Theory indicates no clear trend on both weekly and monthly charts. Overall, the current technical stance is mildly bullish, driven by the weekly MACD and Bollinger Bands, despite some bearish signals on the monthly indicators.

Are Divis Laboratories Ltd latest results good or bad?

Divi's Laboratories Ltd reported a 12.29% year-on-year revenue growth, but faced a concerning 15.38% decline in net profit quarter-on-quarter, indicating mixed performance. While operating margins improved, the profit drop raises questions about the company's near-term sustainability.

Divi's Laboratories Ltd's latest results reveal a mixed performance. While the company reported a year-on-year revenue growth of 12.29%, its net profit saw a significant decline of 15.38% quarter-on-quarter, dropping to ₹583 crores. This decline in profit is concerning, especially since it follows a strong profit increase in the previous quarter.<BR><BR>The revenue for the quarter ended December 2025 was ₹2,604 crores, which is a decrease of 4.09% from the previous quarter. Despite this sequential decline, the year-on-year growth indicates that the company is still managing to expand its sales compared to the same period last year.<BR><BR>On a positive note, the operating margin improved to 34.18%, reflecting strong operational efficiency. However, the overall picture is clouded by the profit decline and the challenges the company faces in a competitive market, including pricing pressures and changing demand patterns.<BR><BR>In summary, while Divi's Laboratories shows strong operational metrics and year-on-year revenue growth, the sequential profit decline raises concerns about its near-term performance and sustainability of growth.

Should I buy, sell or hold Divis Laboratories Ltd?

Which are the latest news on Divi's Lab.?

Why is Divis Laboratories Ltd falling/rising?

As of 03-May, Divis Laboratories Ltd's stock price is 6,505.35, down 0.45%. Despite this decline, the stock has shown strong long-term performance and increased investor interest, though it faces challenges with slow growth and high valuation compared to peers.

As of 03-May, Divis Laboratories Ltd's stock price is currently at 6,505.35, reflecting a decrease of 29.65 points or 0.45%. Despite this decline, the stock has shown positive performance over various time frames, including a 1-week increase of 1.98% and a 1-month rise of 9.40%. The stock has also outperformed the benchmark Sensex over the past year and three years, indicating strong long-term performance.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 0.83%. However, it is trading above its moving averages across multiple time frames, suggesting a generally positive trend. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 31.52% compared to the 5-day average, which may indicate growing interest among investors.<BR><BR>On the positive side, Divis Laboratories has demonstrated high management efficiency with a return on equity (ROE) of 17.24%, is net-debt free, and has reported positive results for the last six consecutive quarters. The company's latest six-month profit after tax (PAT) grew by 20.77%, and it has a high institutional holding of 39.51%, which often reflects confidence from more sophisticated investors.<BR><BR>Conversely, the stock faces challenges due to its relatively poor long-term growth, with net sales increasing at an annual rate of only 9.44% and operating profit at 4.68% over the last five years. The stock is also considered expensive, trading at a premium compared to its peers, with a price-to-book value of 11.2 and a PEG ratio of 3, indicating that its valuation may not be justified by its growth prospects.<BR><BR>In summary, while Divis Laboratories Ltd has shown strong performance metrics and investor interest, its current decline in stock price can be attributed to its recent underperformance relative to the sector and concerns over its long-term growth and valuation.